Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph(+) ALL

Blinatumomab is currently approved for use as a single agent in relapsed and refractory acute lymphoblastic leukemia (ALL). Cytotoxicity is mediated via signaling through the T-cell receptor (TCR). There is now much interest in combining blinatumomab with targeted therapies, particularly in Philadel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Leonard, Jessica T., Kosaka, Yoko, Malla, Pavani, LaTocha, Dorian, Lamble, Adam, Hayes-Lattin, Brandon, Byrd, Kaelan, Druker, Brian J., Tyner, Jeffrey W., Chang, Bill H., Lind, Evan
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7918187/
https://ncbi.nlm.nih.gov/pubmed/32898857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020005655
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados